A global survey of 1,044 healthcare providers reveals that most expectant mothers delay discussing breastfeeding techniques until after delivery or even before the baby arrives. However, experts emphasize the importance of planning and preparation in overcoming breastfeeding challenges. To support expectant mothers, Lansinoh has develo...
A recent study found that approximately 43% of the S-equol in women's plasma is in two biologically active forms after ingestion. These findings suggest that these bioactive forms may contribute to the relief of menopausal symptoms, as reported in previous clinical trials.
A recent study published in the Journal of Health Care for the Poor and Underserved reveals that Non-Hispanic Black Americans have significantly higher rates of nutrient shortfalls compared to Non-Hispanic Whites. The analysis, conducted using data from the National Health and Nutrition Examination Survey (NHANES), found that Blacks we...
A recent analysis published in the Journal of Human Nutrition & Food Science found that dietary magnesium intake is associated with improvements in diabetes-related health outcomes. Adults who met the estimated average requirement for magnesium from food alone had significantly lower odds ratios for metabolic syndrome, obesity, and ele...
A daily snack of 1.5 ounces of almonds significantly improved LDL and total cholesterol levels, reducing central adiposity and improving heart health risk factors. The study also found benefits in reducing abdominal and leg fat mass.
A pilot study found that S-equol supplements improved vaginal epithelium and reduced vaginal atrophy in postmenopausal Japanese women. The supplement showed a positive trend to superiority compared to the placebo group without significant abnormalities in vaginal cells or hormone levels.
Researchers found that almonds can help curb appetites, improve nutrient intake and reduce abdominal fat mass in adults. Snacking on almonds may be a weight-wise strategy depending on the foods consumed, with their nutrient profile supporting a healthy weight.
A new study found that consuming 1.5 ounces of dry-roasted almonds daily reduced participants' hunger and improved their dietary intake of vitamin E and monounsaturated fat without gaining weight. The study, led by Purdue University researchers, suggests almonds may be a smart snack choice to support a healthy weight.
A study found that US women who can produce the compound equol experience larger reductions in menopausal vasomotor symptoms, such as hot flashes, when consuming more soy. Equol has been linked to reduced symptoms in Japanese women and postmenopausal women taking supplements containing it.
A recent study published in the Journal of Women's Health found that a soy-based S-equol supplement reduced hot flash frequency by 3.09-3.66 daily and muscle/joint pain significantly compared to a standard soy isoflavone supplement. The study involved 102 US postmenopausal women who experienced high hot flash frequencies.
A 12-week treatment of a fermented soy germ-based nutritional supplement containing S-equol significantly lowered hemoglobin A1c, LDL cholesterol and improved vascular stiffness in overweight Japanese men and women. The study found favorable effects on metabolic syndrome risk factors, particularly in non-S-equol producing individuals.
A new fermented soy ingredient containing S-equol significantly reduced hot flash frequency in a placebo-controlled study of postmenopausal Japanese women. The supplement also relieved muscle discomfort, including neck and shoulder stiffness.
A new study published in American Journal of Clinical Nutrition found that diets including lean beef every day are as effective in lowering total and LDL 'bad' cholesterol as the 'gold standard' of heart-healthy diets. Participants experienced a 10% decrease in LDL cholesterol from consuming 4.0 oz/day of lean beef daily.
A soy germ-based supplement containing Natural S-equol significantly improved the appearance of crow's feet skin wrinkles in Japanese menopausal women, suggesting potential to slow skin aging. The study found that doses of 10 or 30 milligrams of Natural S-equol daily had beneficial effects on crow's feet wrinkles.
A study published in Food and Chemical Toxicology found that a soy-based natural S-equol supplement did not increase the risk of estrogen-sensitive breast cancer. The supplement, SE5-OH containing Natural S-equol, was previously shown to reduce menopause symptoms in postmenopausal women.
Dr. Napoleone Ferrara has made significant contributions to the understanding of angiogenesis, a process that plays a key role in cancer proliferation and various diseases. His research led to the development of new treatments for age-related macular degeneration and cancer.
A study examining the absorption rates of folic acid from softgel capsules and standard tablets found that bioavailability was similar between the two formulations. The rate of absorption from softgels was slower than tablets, but the average levels of total folate in the blood were similar.
A new study suggests that the soy-based compound Natural S-equol does not increase the risk of estrogen-sensitive breast cancer. Supplements containing SE5-OH have reduced menopause symptoms in postmenopausal women, and the study's findings enhance our understanding of Natural S-equol's safety profile.
A new study suggests that consuming an almond-enriched diet can improve insulin sensitivity and decrease LDL-cholesterol levels in individuals with prediabetes. The study found significant improvements in insulin levels, homeostasis model analysis for insulin resistance, and clinically significant reductions in LDL-cholesterol.
Researchers presented data on natural S-equol, a soy-based compound that mimics some activities of estrogen, to alleviate menopause symptoms. The study findings suggest potential benefits of S-equol for women experiencing diminished estrogen production during menopause.
A new soy-based natural S-equol supplement reduced the frequency of moderate to severe hot flashes and muscle and joint pain in postmenopausal U.S. women. The study found that lower doses of Natural S-equol significantly improved symptoms, with no clinically significant adverse effects.
A new nutritional supplement containing S-equol has been shown to reduce moderate to severe hot flashes, muscle and joint pain, and improve bone density in postmenopausal women. The supplement also lowers 'bad' LDL-cholesterol levels and is considered safe for long-term use.
A new study by the American Lung Association finds that helping smokers quit saves lives and offers significant economic benefits to states. States can expect a 26% return on investment for every dollar spent on smoking cessation treatments, with some states receiving even higher returns.
Drs. De Clercq and Fauci are recognized for their pioneering work in understanding and combating HIV/AIDS. They have made significant contributions to the development of antiviral drugs and treatments.
A study published in the American Journal of Psychiatry found that S-Adenosyl Methionine (SAMe) can effectively treat adults with major depressive disorders who do not respond to antidepressant medication. The supplement was well-tolerated and improved measures of depression and remission rates compared to a placebo.
Research suggests that SE5-OH containing Natural S-equol can help alleviate hot flushes and other menopausal symptoms. Additionally, studies have found that soy-based diets may help prevent bone loss in postmenopausal women.
A new study examines the safety and tolerance of SE5-OH containing Natural S-equol in healthy adult Japanese men, with results showing normal hormone levels and PSA levels. The supplement appears to be well-tolerated, but further studies are needed to confirm its effects on prostate health.
SE5-OH containing natural S-equol significantly reduced frequency of hot flushes in postmenopausal women. The compound had no effect on reproductive hormones E2 and FSH, suggesting its potential as a critical component in reducing menopausal symptoms.
Two clinical trials found SE5-OH with Natural S-equol to be safe and well-tolerated in both pre- and post-menopausal women, with no significant impact on reproductive hormones or menstrual cycle length. The supplement showed promise in reducing hot flashes in post-menopausal women.
INTUNIV, a selective alpha-2A agonist, shows no unique adverse effects when coadministered with amphetamine or methylphenidate. The study demonstrated improved ADHD symptoms using the ADHD Rating Scale-IV (ADHD-RS-IV) in children and adolescents.
A post hoc analysis of Phase 3 study data found that Vyvanse significantly improved emotional lability composite CPRS-RS scores in children with ADHD aged 6 to 12 years. Treatment with Vyvanse yielded significant improvements in emotional lability scores only for those with prominent emotional lability prior to treatment.
A Phase IIIb study of Daytrana found significant improvements in ADHD symptoms in adolescents aged 13-17 years, with most adverse events mild to moderate. Pharmacokinetic data also showed similar exposure to d-MPH in both children and adolescents.
Shire presents new scientific data on its ADHD portfolio, including INTUNIV, Vyvanse, and Daytrana. The company's ADHD business unit is committed to advancing treatment research and developing safe and effective treatments.
INTUNIV demonstrated significant efficacy in reducing symptoms of attention deficit hyperactivity disorder (ADHD), particularly oppositional symptoms, in children and adolescents. The study showed improved symptoms as measured by the Conners' Parent Rating Scale-Revised: Long Form (CPRS-R:L) and ADHD Rating Scale-IV (ADHD-RS-IV).
A clinical trial found that a supplement containing SE5-OH and Natural S-equol improved menopausal symptoms, including reducing hot flashes by 58.7 percent, in postmenopausal Japanese women. The study also showed positive improvements in other menopause symptoms.
A study found that Vyvanse significantly reduced ADHD symptoms in children aged 6-12 from 1.5 to 13 hours after taking the medication. The study, published online in Child and Adolescent Psychiatry and Mental Health, demonstrated long-lasting efficacy of Vyvanse in improving behavior and attention.
In a simulated workplace environment study, VYVANSE CII improved ADHD symptoms of inattention, hyperactivity, and impulsivity, as measured by the Permanent Product Measure of Performance (PERMP) and ADHD Rating Scale (ADHD-RS). Adults taking VYVANSE showed significant efficacy at 14 hours after administration.
A phase 2 trial of TMC207 for MDR-TB found a significant increase in sputum culture negativity and reduced time to conversion compared to the background regimen. The results validate ATP synthase as a potential treatment target.
Coadministration of Prilosec OTC 40 mg did not alter maximum plasma concentration or area under curve for active medication in both VYVANSE and ADDERALL XR. The study also found a significant reduction in time to reach maximum plasma concentrations of amphetamine with coadministration of Prilosec OTC 40 mg.
INTUNIV demonstrated significant efficacy in treating ADHD symptoms, particularly in children aged 6-12 years with oppositional behaviors. The study showed improved symptom reduction on various rating scales, including the ADHD Rating Scale-IV and Clinical Global Impressions-Improvement.
Shire plc will present key scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments lisdexamfetamine dimesylate and investigational non-scheduled guanfacine extended release. The presentations include studies on the pharmacokinetics, duration of effects, patient experience, and response to treatment.
The 'Cradle & Grave' white paper examines seismic changes in birth, health, and death trends, influencing the future administration and Americans contemplating their futures. Gary Stockman highlights outdated assumptions shaping unrealistic expectations and poor choices.
DeCODE's DNA-based risk tests have been shown to increase accuracy of MI risk prediction by measuring genetic markers on chromosomes 9p21 and 4q25. These tests provide a new tool for improving screening, prevention, and treatment of cardiovascular conditions.
The study found that VYVANSE controlled ADHD symptoms from the first time point measured through the last time point assessed. In addition, VYVANSE treatment was associated with significant improvement in math problems attempted and answered correctly for up to 13 hours post-dose.
A phase III pivotal study showed VYVANSE significantly improved ADHD symptoms in adults, including inattention and hyperactivity. The medication provided a 43% reduction in ADHD Rating Scale (ADHD-RS-IV) scores and was associated with a 60% improvement rate on the Clinical Global Impressions-Improvement (CGI-I) scale.
INTUNIV, a selective alpha-2A receptor agonist, demonstrated significant efficacy in reducing ADHD symptoms across all measured time points up to 24 hours postdose. The medication showed improved symptoms of ADHD in patients treated with INTUNIV compared to those receiving placebo.
A new data analysis confirms DAYTRANA's effectiveness in controlling ADHD symptoms in both boys and girls for up to 12 months. The study found that children with ADHD experienced significant improvements in symptom control, with lower scores on the ADHD Rating Scale.
Shire will present efficacy and safety results for its ADHD treatments, including lisdexamfetamine dimesylate, methylphenidate transdermal system, and guanfacine extended release. The presentations aim to contribute to the growing body of research on ADHD treatment options.
Researchers found that Enbrel significantly reduced levels of C-reactive protein in patients with moderate to severe plaque psoriasis, indicating a systemic inflammatory disease. The study also showed that heavier patients had higher CRP levels and that Enbrel decreased these levels in overweight and obese patients.
A national survey of parents with children aged 6-17 found that 60% reported their child's medication stopped working before 6 p.m. This suggests a need for reassessment of treatment duration and potential factors contributing to the perceived ineffectiveness.